CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 204 enrolled
Drug / intervention
Placebo / Teneli (Teneligliptin) + pio (pioglitazone) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01026194
NCT01026194Phase 3Completed
CompareCT.gov

A Phase III Study of MP-513 in Combination With Thiazolidinedione in Japanese Patients With Type 2 Diabetes Mellitus

Tanabe Pharma Corporation·interventional·Posted Dec 4, 2009·Updated Jan 5, 2026

In Brief

A Phase 3 clinical trial evaluating Placebo / Teneli (Teneligliptin) + pio (pioglitazone) and Teneli / Teneli + pio for Type 2 Diabetes Mellitus. Completed, enrolled 204 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with thiazolidinedione (pioglitazone) in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with thiazolidinedione with an extension treatment for up to 52 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 4, 2009
Enrollment StartDec 1, 2009
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.6 years ago

Interventions

Placebo / Teneli (Teneligliptin) + pio (pioglitazone)drug

Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.

Teneli / Teneli + piodrug

Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.